The Thrombosis drugs in development market research report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thrombosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thrombosis and features dormant and discontinued products.
GlobalData tracks 141 drugs in development for Thrombosis by 117 companies/universities/institutes. The top development phase for Thrombosis is preclinical with 65 drugs in that stage. The Thrombosis pipeline has 118 drugs in development by companies and 23 by universities/ institutes. Some of the companies in the Thrombosis pipeline products market are: Bristol-Myers Squibb, Jiangsu Hengrui Medicine and Glycan Therapeutics.
The key targets in the Thrombosis pipeline products market include Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27), Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6), and Coagulation Factor XII (Hageman Factor or HAF or F12 or EC 3.4.21.38).
The key mechanisms of action in the Thrombosis pipeline product include Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Inhibitor with 23 drugs in Phase III. The Thrombosis pipeline products include ten routes of administration with the top ROA being Oral and 15 key molecule types in the Thrombosis pipeline products market including Small Molecule, and Monoclonal Antibody.
Thrombosis overview
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a clot dislodges and travels to the lungs. Risk factors for thrombosis include immobility, surgery, certain medical conditions, and genetic factors. Treatment may involve anticoagulant medications to prevent clot formation, and in severe cases, interventions like thrombectomy or placement of a filter in the blood vessel may be considered.
For a complete picture of Thrombosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
